A. Baur & CO. (pvt.) Ltd Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: A. Baur & CO. (pvt.) Ltd Pharmaceutical Import Records from India — 2 Products, $308.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

A. Baur & CO. (pvt.) Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $308.0K Trade | TransData Nexus

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Soframycin	Brand Names & OTC Products	$208.0K	11	34.7%	1
2	Glibenclamide	Advanced Diabetes Medications	$100.0K	2	0.2%	1

A. Baur & CO. (pvt.) Ltd imports 2 pharmaceutical products across 2 categories into Sri Lanka totaling $308.0K. The company is the #1 buyer for 2 products: Soframycin, Glibenclamide.

A. Baur & CO. (pvt.) Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

A. Baur & Co. (Pvt.) Ltd, commonly known as Baurs, is a prominent conglomerate in Sri Lanka, established in 1897 by Swiss national Alfred Baur. The company has diversified its operations across various sectors, including agriculture, healthcare, industrial raw materials, and consumer goods. Headquartered at 5 Upper Chatham Street, Colombo 1, Sri Lanka, Baurs employs over 800 individuals across its multiple divisions.

In the pharmaceutical sector, Baurs has a significant presence, importing and distributing a range of world-renowned brands from leading multinational corporations and reputable manufacturers. Their distribution network spans the entire island, ensuring comprehensive coverage. The company operates a state-of-the-art IT system that integrates its retail, wholesale, and distribution networks, optimizing efficiency and providing real-time data access to all stakeholders.

2Distribution Network

Baurs operates a comprehensive distribution network that reaches all regions of Sri Lanka, providing national coverage for its customers. The company boasts a state-of-the-art warehousing facility with 20,000 square feet of ambient temperature-controlled storage space and a 1,500 cubic foot cold storage facility equipped with continuous temperature logging and remote sensing alarm systems. These facilities comply with WHO Good Storage Practices (GSP) guidelines and meet the requirements of reputed multinational suppliers.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, A. Baur & Co. (Pvt.) Ltd functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers. Baurs' extensive distribution network and integrated IT systems enable efficient delivery of pharmaceutical products across the island, serving both public and private healthcare sectors.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — A. Baur & CO. (pvt.) Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Baurs' sourcing strategy exhibits a high degree of concentration, with a portfolio focused on a limited number of products. The company's import data indicates that its top five products account for 100% of its pharmaceutical imports from India, highlighting a single-source dependency. This concentration may pose risks related to supply chain disruptions, pricing volatility, and regulatory changes affecting specific products. However, it also suggests a strategic choice to specialize in high-demand, high-value products, potentially leading to stronger relationships with suppliers and better negotiation leverage.

2Supply Chain Resilience

The resilience of Baurs' supply chain is influenced by its concentrated sourcing strategy. While the company imports finished pharmaceutical formulations from India, the lack of publicly available information on backup suppliers and the diversity of its product formulations makes it challenging to assess the robustness of its supply chain fully. The company's compliance with WHO Good Storage Practices and its state-of-the-art warehousing facilities indicate a commitment to maintaining product quality and mitigating potential disruptions.

3Strategic Implications

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary drug regulatory body in Sri Lanka, responsible for regulating and evaluating medicinal products, devices, cosmetics, and manufacturing facilities. The NMRA issues wholesale licenses, retail licenses, and transport licenses for medicinal products and devices. It also controls the pricing for selected drugs and devices in the Sri Lankan market and oversees the approval of labeling and advertising. (freyrsolutions.com.lk)

2Import Licensing & GMP

Import licensing requirements in Sri Lanka are governed by the NMRA, which issues licenses for the importation of pharmaceutical products. Good Manufacturing Practice (GMP) certificates recognized by the NMRA include those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply pharmaceutical products to Sri Lanka must ensure that their manufacturing facilities hold valid GMP certifications recognized by the NMRA. (freyrsolutions.com.lk)

3Quality & Labeling

A. Baur & CO. (pvt.) Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Baurs' product strategy focuses on importing and distributing high-demand pharmaceutical products, particularly in the therapeutic areas of Brand Names & OTC Products and Advanced Diabetes Medications. The company's import data indicates that these categories constitute 67.5% and 32.5% of its pharmaceutical imports from India, respectively. This focus aligns with market demand for effective treatments in these areas, reflecting Baurs' commitment to meeting the healthcare needs of the Sri Lankan population.

2Sourcing Profile

Baurs' sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India. The company's portfolio is concentrated on a limited number of products, indicating a strategic choice to specialize in high-demand, high-value items. This approach allows Baurs to leverage supplier relationships and market expertise, ensuring a consistent supply of quality products to the Sri Lankan market.

3Market Positioning

Based on its product mix, Baurs serves a broad segment of the Sri Lankan pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive distribution network and integrated IT systems enable efficient delivery of pharmaceutical products across the island, catering to the diverse needs of the healthcare sector.

Seller's Guide — How to Become a Supplier to A. Baur & CO. (pvt.) Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Baurs, particularly in the therapeutic areas of Brand Names & OTC Products and Advanced Diabetes Medications. The company's concentrated sourcing strategy indicates a preference for specialized products, and establishing a reliable supply chain can lead to a mutually beneficial partnership. However, potential suppliers must ensure compliance with Sri Lankan import regulations, including obtaining the necessary GMP certifications recognized by the NMRA.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Baurs and the Sri Lankan market must obtain GMP certifications recognized by the NMRA, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with NMRA guidelines for batch testing, stability requirements, labeling language, and serialization is essential. Adhering to these standards ensures product quality and facilitates a smooth import process. (freyrsolutions.com.lk)

3How to Approach

Frequently Asked Questions — A. Baur & CO. (pvt.) Ltd

What products does A. Baur & CO. (pvt.) Ltd import from India?

A. Baur & CO. (pvt.) Ltd imports 2 pharmaceutical products across 2 categories. Top imports: Soframycin ($208.0K), Glibenclamide ($100.0K).

What is A. Baur & CO. (pvt.) Ltd's total pharmaceutical import value?

A. Baur & CO. (pvt.) Ltd's total pharmaceutical import value from India is $308.0K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does A. Baur & CO. (pvt.) Ltd focus on?

A. Baur & CO. (pvt.) Ltd imports across 2 categories. The largest: Brand Names & OTC Products (67.5%), Advanced Diabetes Medications (32.5%).

Get Full A. Baur & CO. (pvt.) Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

A. Baur & CO. (pvt.) Ltd

A. Baur & CO. (pvt.) Ltd — Import Portfolio & Supplier Network

What Products Does A. Baur & CO. (pvt.) Ltd Import?

Top Products by Import Value

A. Baur & CO. (pvt.) Ltd Therapeutic Categories — 2 Specializations